MEDIF (MediPharm Labs) Gross-Profit-to-Asset % : 21.70% (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is MediPharm Labs Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. MediPharm Labs's annualized Gross Profit for the quarter that ended in Sep. 2024 was $9.21 Mil. MediPharm Labs's average Total Assets over the quarter that ended in Sep. 2024 was $42.44 Mil. Therefore, MediPharm Labs's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 was 21.70%.

MediPharm Labs Gross-Profit-to-Asset % Historical Data

The historical data trend for MediPharm Labs's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MediPharm Labs Gross-Profit-to-Asset % Chart

MediPharm Labs Annual Data

Trend

Sep17

Sep18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

50.70

-31.14

-14.48

-2.34

9.10

MediPharm Labs Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															13.53	13.37	16.86	22.44	21.70

Competitive Comparison of MediPharm Labs's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, MediPharm Labs's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MediPharm Labs's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, MediPharm Labs's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where MediPharm Labs's Gross-Profit-to-Asset % falls into.

MediPharm Labs Gross-Profit-to-Asset % Calculation

MediPharm Labs's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	4.364	/	( (48.211	+	47.657)	/ 2 )
	=	4.364	/	47.934
	=	9.10 %

MediPharm Labs's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
	=	9.212	/	( (43.664	+	41.225)	/ 2 )
	=	9.212	/	42.4445
	=	21.70 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Sep. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

MediPharm Labs Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of MediPharm Labs's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

MediPharm Labs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MediPharm Labs Corp (OTCPK:MEDIF) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

MLZ:Germany LABS:Canada

Address

151 John Street, Barrie, ON, CAN, L4N 2L1

Website

https://www.medipharmlabs.com

MediPharm Labs Corp is a pharmaceutical company specializing in precision-based cannabinoids. The Company operates in one reportable segment, the production and sales of cannabis flower, extracts, and derivative products. Through its wholesale and white-label platforms, MediPharm Labs formulates, develops, processes, packages, and distributes cannabis extracts and cannabinoid-based products to domestic and international markets. Geographically the company has a presence in Canada, Australia, Germany, and other countries and the majority of revenue derives from Canada.